PGxAI Named a Key Player in Straits Research’s Pharmacogenomics (PGX) Market Report

PALO ALTO, Calif., Sep. 22, 2025 — PGxAI has been recognized by Straits Research in its latest Pharmacogenomics (PGX) Market Size, Share & Trends Analysis Report (2025–2033), where the company is listed among the key market players and profiled as an emerging innovator in AI‑driven pharmacogenomics.

According to the report, the global pharmacogenomics market was valued at $6.13B in 2024 and is projected to reach $11.17B by 2033 at a 6.6% CAGR—underscoring accelerating adoption of AI, bioinformatics, and EHR‑integrated decision support across clinical workflows.

“We’re honored to be included by Straits Research as part of the industry’s leading cohort,” said Dr. Mike Zack, co‑founder and CEO of PGxAI. “This recognition reflects our focus on turning complex genomic and clinical evidence into precise, point‑of‑care recommendations that help clinicians reduce adverse drug reactions and improve outcomes.”

Straits Research highlights the growing role of AI/ML‑enabled platforms in scaling pharmacogenomic insights and improving turnaround time for guideline‑concordant prescribing—areas central to PGxAI’s product roadmap and health‑system integrations.

About PGxAI PGxAI is an AI‑driven precision‑medicine company that transforms multi‑omics and clinical data into real‑time, gene‑guided prescribing support for health systems, payors, and life sciences partners.